Global pharma company with branded generics, specialty and innovative oncology/dermatology/respiratory portfolios across 80+ countries.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 |
| Reserves | 13.2k | 14.8k | 16.7k | 17.8k | 22.9k | 24.5k | 23.9k | 24.1k |
| Borrowings | 3.6k | 3.7k | 3.7k | 3.2k | 707 | 830 | 476 | 107 |
| Other Liabilities | 2.2k | 2.1k | 2.4k | 3.5k | 3.7k | 2.7k | 4.0k | 5.2k |
| Total Liabilities | 19.0k | 20.6k | 22.9k | 24.6k | 27.4k | 28.0k | 28.4k | 29.5k |
| AssetsFixed Assets | 1.6k | 1.7k | 1.8k | 1.7k | 1.8k | 2.0k | 2.0k | 2.1k |
| CWIP | 200 | 131 | 109 | 172 | 198 | 155 | 168 | 67 |
| Investments | 4.7k | 7.0k | 8.6k | 10.3k | 13.0k | 15.2k | 15.2k | 15.2k |
| Other Assets | 12.4k | 11.8k | 12.5k | 12.3k | 12.5k | 10.7k | 11.0k | 12.1k |
| Total Assets | 19.0k | 20.6k | 22.9k | 24.6k | 27.4k | 28.0k | 28.4k | 29.5k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 2.5k | 1.6k | 1.2k | 1.2k | 1.5k | -495 | 589 | 54 |
| Cash from Investing | -2.3k | -1.6k | -1.2k | -897 | -432 | 3.2k | -490 | 57 |
| Cash from Financing | -155 | -139 | -81 | -305 | -978 | -2.7k | -95 | -95 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 2.9k | 1.6k | 1.1k | 1.1k | 1.6k | -690 | 249 | 27 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
GLENMARK · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.